TXMD

2.07 +0.00%
TherapeuticsMD, Inc. NASDAQ Stock Pharmaceutical Stocks
Open in Risen →

TherapeuticsMD, Inc. (TXMD) is listed on NASDAQ in the Manufacturing sector. This page tracks real-time TXMD price, technical indicators including RSI, MACD, and the 52-week range, plus fundamentals, earnings history, and recent insider trading activity.

Technical Analysis

RSI (14) 59.3 Neutral
Market Cap $24.0M
Volume 14.6K

Fundamentals — 10-Q Q2 2026

Revenue --
Net Income $250,000
EPS $0.02
P/E Ratio 103.5x

Earnings

Recent Insider Trades

Name Title Type Shares Price Value Date
Thompson Tommy G Director Buy 8,400 $1.67 $14,028 2025 Dec 23
Thompson Tommy G Director Buy 325 $1.00 $325 2025 Apr 14
Walker Marlan D Chief Executive Officer Buy 490 $1.00 $490 2025 Apr 14
Walker Marlan D Chief Executive Officer Buy 2,303 $0.86 $1,992 2025 Apr 10
Collins Cooper C. Director Buy 4,094 $1.73 $7,083 2024 Aug 22
Collins Cooper C. Director Buy 1,200 $1.70 $2,040 2024 Aug 21
Walker Marlan D Chief Executive Officer Sell 19,050 $2.29 $43,687 2023 Dec 7
Walker Marlan D Chief Executive Officer Sell 1,170 $3.65 $4,271 2023 Apr 12
Donegan Michael C Prin. Fin. and Acctg. Officer Sell 1,697 $5.08 $8,621 2023 Jan 27
Donegan Michael C Prin. Fin. and Acctg. Officer Sell 1,309 $5.34 $6,990 2023 Jan 24
Rosen David Efraim 10% Owner Sell 29,000 $1333.00 $38.7M 2022 Dec 30
Rosen David Efraim 10% Owner Buy 14,825 $6.09 $90,284 2022 Dec 9
Bernick Brian Co-Chief Executive Officer Sell 1,255 $5.27 $6,619 2022 Dec 9
Rubric Capital Management LP 10% Owner Buy 20,413 $5.66 $115,589 2022 Dec 8
Naughton Gail K Director Sell 3,922 $5.26 $20,630 2022 Dec 7
Donegan Michael C Interim CFO/CAO/VP of Finance Sell 910 $4.78 $4,350 2022 Dec 6
Glickman Mark A Co-Chief Executive Officer Sell 440 $4.92 $2,165 2022 Dec 6
Walker Marlan D General Counsel Sell 1,048 $4.95 $5,188 2022 Dec 6
Rosen David Efraim 10% Owner Buy 7,000 $1000.00 $7.0M 2022 Oct 28
Rosen David Efraim 10% Owner Buy 7,000 $1000.00 $7.0M 2022 Sep 30

Take TXMD further

Set alerts on TXMD

Get notified when TherapeuticsMD, Inc. hits your price targets or technical conditions are met.

Get Started Free